Tenapanor

What is Tenapanor

Tenapanor is a sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for irritable bowel syndrome with constipation (IBS-C) in adults.

Tenapanor is minimally absorbed from the GI tract and acts locally to increase bowel movements and decrease abdominal pain. In clinical studies, tenapanor demonstrated a statistically significant reduction in constipation and abdominal pain in adults with IBS-C.

The primary endpoints were at least a 30% reduction in the weekly average abdominal pain score compared with baseline and an increase of at least 1 complete spontaneous bowel movement (CSBM) in weekly average from baseline, in the same week, for at least 6 of the first 12 treatment weeks. In both trials, patients receiving tenapanor met the primary endpoints (Trial 1: 37% versus 24% placebo, Trial 2: 27% versus 19% placebo).

Tenapanor carries a boxed warning for risk of serious dehydration in pediatric patients. Tenapanor was approved by the FDA in September 2019.

Brand Name

IBSRELA

Indications

  • constipation
  • irritable bowel syndrome

For the treatment of irritable bowel syndrome with constipation (IBS-C)

Side Effects

  1. abdominal pain
  2. dehydration
  3. diarrhea
  4. diarrhea
  5. dizziness
  6. flatulence
  7. GI bleeding
  8. hyperkalemia

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • abdominal pain
  • breast-feeding
  • children
  • cholelithiasis
  • Crohn’s disease
  • diarrhea
  • diverticulitis
  • fecal impaction
  • gastric cancer
  • GI disease
  • GI obstruction
  • infants
  • inflammatory bowel disease
  • neonates
  • pregnancy

Interactions

No information is available regarding drug interactions associated with Tenapanor 

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856
Scroll to Top